Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $900.00 Price Target at Wells Fargo & Company

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price reduced by analysts at Wells Fargo & Company from $1,050.00 to $900.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 22.68% from the company’s current price.

Several other brokerages also recently weighed in on REGN. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price for the company. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Barclays cut their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $1,037.33.

Regeneron Pharmaceuticals Stock Up 0.5 %

REGN opened at $733.59 on Friday. Regeneron Pharmaceuticals has a twelve month low of $693.00 and a twelve month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a 50 day moving average price of $754.37 and a 200-day moving average price of $965.13. The stock has a market capitalization of $80.61 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 2.19 and a beta of 0.10.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rakuten Securities Inc. grew its stake in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $26,000. Fairfield Financial Advisors LTD acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $37,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $39,000. Finally, Truvestments Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $39,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.